Laar, M.A.F.J. van de

Rasker, J.J.

Taal, E.

Zijlstra, T.R.

English

Taal, Erik

van de Laar, Mart A F J

Rasker, Johannes J.

NARCIS 

Validation of a Dutch translation of the fibromyalgia impact questionnaire

University of Twente Research Information

Table 3. Non-parametric Spearman’s rho correlations between FIQ and other outcomes for 224 subjects with fibromyalgia  MPQ- PRI-T  CIS-Activity CIS-Subjective  BDI  TPS  GTPS Physical function .24*** .33*** .43*** .26*** .22** .14* Days felt good 1 .32*** .29*** .39*** .29*** .11 -.03 Work days missed 2 .24* .12 .26* .08 -.01 .05 Job ability  .35*** .28*** .42*** .35*** .16* .16* Pain .44*** .26*** .43*** .36*** .09 .11 Fatigue .25*** .37*** .61*** .44*** .09 .06 Morning tiredness .29*** .26*** .53*** .34*** .05 .04 Stiffness .28*** .22*** .41*** .24*** .06 .07 Anxiety  .33*** .26*** .30*** .52*** .03 -.00 Depression .24*** .31*** .27*** .54*** -.03 -.11 * p0.05; ** p0.01; *** p 0.001 1 n = 222 2 n = 93;   Table 4. Sensitivity to change of FIQ for three weeks of SPA treatment  n Baseline Mean (SD) 6 weeks change mean (SD) SRM 95% CI Physical function 56 4.5 (1.7)  1.0 (1.6)** 0.6 0.3 to 0.9 Days felt good 56 7.3  (2.4)  3.1 (3.4)** 0.9 0.6 to 1.2 Work days missed 22 0.8 (2.4)  0.4 (1.2) 0.3 -0.1 to 0.7 Job ability  56 5.8  (2.1)  1.5 (2.8)** 0.5 0.2  to 0.8 Pain 56 5.9  (1.8)  1.6 (2.3)** 0.7 0.4 to 1.0 Fatigue 56 6.6  (1.9)  1.6 (2.8)** 0.6 0.3 to 0.9 Morning tiredness 56 6.7  (1.7)  1.5 (2.6)** 0.6 0.3 to 0.9 Stiffness 56 6.4  (2.0)  1.9 (2.7)** 0.7 0.4 to 1.0 Anxiety  56 3.7  (2.8)  1.3 (2.7)** 0.5 0.2 to 0.8 Depression 56 2.5  (2.4)  0.7 (2.1)* 0.3 0.0 to 0.6 * p0.01; ** p0.001 for Wilcoxon signed rank test comparing baseline and 1 month scores    Table 5. Sensitivity to change of FIQ for experienced general improvement after 6 weeks of treatment with venlafaxine or placebo  Improved (n=30) Not improved (n=60)  Baseline mean (SD) Mean  Change (SD) SRM 95% CI Baseline mean (SD)Mean  Change (SD) SRM 95% CI Physical function  4.4 (1.6)  0.9 (1.3)** 0.7 0.3 to 1.1 4.9 (1.8) -0.1 (1.0) -0.1 -0.4 to 0.2 Days felt good  4.0 (2.2)  3.1 (2.1)** 1.5 1.1 to 1.9 4.6 (2.2) 0.1 (2.3) 0 -0.3 to 0.3 Work days missed1 0.4 (1.3) -0.6 (2.2) -0.3 -0.9 to 0.3 2.5 (2.9) 0.3 (1.6) 0.2 -0.2 to 0.6 Job ability  6.3 (2.1)  2.1 (2.3)** 0.9 0.5 to 1.3 5.7 (2.3) -1.0 (2.7)* -0.4 -0.7 to -0.1 Pain 6.4 (1.8)  1.9 (2.2)** 0.9 0.5 to 1.3 6.6 (1.7) -0.2 (1.9) -0.1 -0.4 to 0.2 Fatigue 6.8 (1.9)  1.4 (2.2)* 0.6 0.2 to 1.0 6.8 (2.2) -0.3 (1.9) -0.2 -0.5 to 0.1 Morning tiredness 7.1 (1.9)  2.5 (3.6)* 0.7 0.3 to 1.1 7.4 (2.3) 0.1 (2.0) 0.1 -0.2 to 0.4 Stiffness 6.8 (1.7)  2.3 (2.4)** 1.0 0.6 to 1.4 6.6 (2.3) 0.1 (2.3) 0 -0.3 to 0.3 Anxiety  3.6 (2.6)  1.0 (2.8) 0.4 0.0 to 0.8 3.9 (3.1) 0    (2.4) 0 -0.3 to 0.3 Depression 3.3 (2.8)  1.8 (2.8)* 0.6 0.2 to 1.0 2.7 (3.0) 0    (2.2) 0 -0.3 to 0.3 * p0.01; ** p 0.001 1 work days missed: improved (n=11); not improved (n=20)  

Arthritis Rheum-Arthritis Care Res

Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the Fibromyalgia Impact Questionnaire.

Cognitive therapy of depression.

De Nederlandse versie van de ‘McGill pain Questionnaire’: een betrouwbare pijnvragenlijst. Ned Tijdschr Gen

der Heide A et al. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res

Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders.

Health-related quality of life in chronic disorders: a comparison across studies using the MOS

Health-related quality of life in primary Sjogren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36.

Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum

Noordelijk Centrum voor Gezondheidsvraagstukken;

Quality of life in women with fibromyalgia syndrome: validation of the QIF, the french version of the fibromyalgia impact questionnaire.

Report of the Multicenter Criteria Committee. Arthritis Rheum

Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life.

Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum,

The American College of Rheumatology

The Fibromyalgia Impact Questionnaire, a Swedish translation of a new tool for evaluation of the fibromyalgia patient.

The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia.

The fibromyalgia impact questionnaire: development and validation.

The McGill Pain Questionnaire: major properties and scoring method.

Tijdschr Psychol Grensgeb

Validation of a Korean version of the Fibromyalgia Impact Questionnaire.

Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I). Clin Exp Rheumatol 2003;21:459–64. 10. Dunkl PR,

Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, doubleblind trial.

https://research.utwente.nl/en/publications/bdc5a653-14fa-4f76-af57-0ab0d0d91b65

Validation of a Dutch translation of the fibromyalgia impact questionnaire

Abstract

Similar works

Full text

Available Versions

NARCIS

University of Twente Research Information